Who We Work With
Strategic growth and commercialization of advanced materials for healthcare
SMALL Bio partnered directly with the CEO and leadership team of Rousselot to define and execute the growth strategy for its Biomedical division. Together, we identified and developed new commercial opportunities across drug delivery, regenerative medicine, tissue engineering, medical devices, advanced therapeutics, and Cell & Gene Therapy.
We led the development of the division's business plan and investment case, securing internal funding to accelerate growth initiatives. In parallel, we originated strategic partnerships, structured in-licensing and out-licensing opportunities, and drove key account acquisition, resulting in a multimillion-dollar commercial sales pipeline.
Through a combination of scientific, commercial, and strategic leadership, SMALL Bio helped establish a scalable framework for business development, venture creation, and long-term value generation, strengthening Rousselot Biomedical's position as a leading innovator in advanced healthcare materials
Strategic repositioning and commercialization of AI-powered drug development platforms
SMALL Bio led the strategic repositioning of DeepLife from a technology company with broad capabilities into a pharmaceutical and biotechnology solutions platform supporting critical decisions across the drug development lifecycle.
We developed the commercial framework and value proposition for applications spanning target identification, indication expansion, patient stratification, clinical trial planning, predictive analytics for product positioning and reimbursement, and drug repositioning. To accelerate growth, we implemented a data-driven business development model based on continuous monitoring of pharmaceutical pipelines, enabling systematic identification and prioritization of high-value commercial opportunities.
Beyond strategy, we drove commercial execution by engaging leading pharmaceutical companies, establishing key accounts, and leading business development from initial engagement through contract negotiation and delivery of the company's first commercial projects. Through this approach, we transformed a nascent commercial organization into a mature business development function, generating a qualified commercial pipeline valued at more than €15 million.
Strategic repositioning, commercialization, fundraising, and transaction execution
SMALL Bio partnered with IAMFluidics to transform a promising deep-tech platform into a venture positioned for pharmaceutical growth and strategic acquisition. We led the company's repositioning from cosmetics and nutraceutical applications toward high-value pharmaceutical drug delivery, advanced therapeutics, and Cell & Gene Therapy manufacturing markets.
Beyond strategy development, we drove commercial execution by identifying and securing seven strategic key accounts, generating a qualified commercial pipeline exceeding €15 million. We structured and led fundraising activities, developed investor engagement strategies, and established critical industry partnerships that accelerated market adoption.
As the company matured, SMALL Bio played a central role in structuring and negotiating a strategic transaction pathway that ultimately positioned the business for acquisition in a deal valued at more than €35 million.
Strategic transformation and commercialization of advanced manufacturing technologies
HOYA, a global leader in advanced glass technologies, engaged SMALL Bio to identify and execute new growth opportunities for precision manufacturing infrastructure and intellectual property originally developed for hard-disk platter production.
SMALL Bio developed and validated the commercial strategy for expansion into diagnostics and biomedical applications, defining the market-entry pathway and business case for investment. We designed manufacturing workflows for diagnostics production, established GMP-compatible operational processes, and built the commercial and customer engagement infrastructure required to support market adoption.
Through a combination of strategic, operational, and commercial leadership, SMALL Bio enabled the successful launch of a new diagnostics business unit, generating more than $21 million USD in first-year revenue.
Strategic repositioning and commercialization of advanced manufacturing technologies
SMALL Bio led the strategic repositioning of FDX Fluid Dynamix, transforming an advanced mixing technology platform into a solution for GMP-grade manufacturing of lipid nanoparticles supporting mRNA vaccines and advanced therapeutics.
We developed the commercial strategy, identified high-value pharmaceutical applications, and established a market-entry pathway aligned with the rapidly growing nucleic acid therapeutics sector. Working across technical, operational, and commercial functions, we positioned the technology to meet the requirements of pharmaceutical manufacturing and advanced therapy production.
The project resulted in a strategic partnership with a leading European contract development and manufacturing organization, securing an upfront commercial agreement valued at more than €5 million, alongside a multi-million-euro recurring licensing arrangement. The engagement established a clear pathway for long-term growth and value creation within the pharmaceutical manufacturing sector.
Strategic repositioning and commercialization of integrated manufacturing systems
SMALL Bio led the strategic repositioning of Advanced Microfluidics from a supplier of OEM microfluidic components to a provider of customized manufacturing equipment and software solutions for pharmaceutical and biomedical applications.
We developed the commercial strategy and value proposition, shifting the business toward higher-value, customer-specific systems that combined advanced hardware with proprietary software and process expertise. This transformation significantly strengthened the company's competitive positioning while improving margin potential across its product portfolio.
In parallel, we drove business development, secured key pharmaceutical and biomedical accounts, and established a foundation for long-term commercial growth. The project resulted in a substantial expansion of the company's market presence and contributed to a doubling of annual revenues.
Venture development and commercialization of advanced molecular imaging technologies
SMALL Bio partnered with NanoInk Imaging to transform a promising academic technology into a commercially scalable platform for oncology imaging and immunotherapy applications. We led the development of the company's contrast agent manufacturing strategy, transitioning production from a research-based capability to an automated GMP-compliant manufacturing platform capable of supporting clinical and commercial deployment.
In parallel, we positioned the technology for immunotherapy applications, developed the company's five-year operating model, and established the commercial and strategic framework required for long-term growth. We also led fundraising activities and investor engagement to support the company's development objectives.
Beyond strategy and operations, we drove business development and key account acquisition, securing early commercial engagements with leading industry organizations and establishing the foundation for future growth. The project resulted in the company's first commercial contracts and revenues, validating both the technology platform and its market potential.
Venture creation and commercialization of single-cell analysis technologies
SMALL Bio supported SIORA from its inception, leading the creation and development of the company from an academic technology platform into a commercially focused life science venture. We established the business model, defined the commercialization strategy, and positioned the company around high-value applications in antibody discovery and single-cell genomics.
To accelerate growth, we secured academic grant funding, supported fundraising activities, and developed strategic partnerships across the biotechnology ecosystem. In parallel, we drove early commercial engagement, helping translate scientific innovation into customer-focused products and market opportunities.
The project resulted in the successful manufacture of SIORA's first commercial devices, the establishment of key strategic partnerships, and the signing of its first commercial contracts. Today, SIORA is successfully transitioning from the academic environment into an independent biotechnology company with a growing commercial presence.